MAP2K7 and schwannoma: Dysregulation of RAS–MEK–ERK and mTORC1/2 signaling has been shown to promote tumorigenesis in NF2-associated schwannomas and meningiomas, and inhibition of these pathways has shown promise in multiple therapeutic trials in NF2 patients.